Technology

As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR has evolved from the initial discovery of the double helix to now, with the technology holding great promise for both genetic diseases and cancers.

The growth in telehealth utilization continued an increase begun in November 2022.

A feasibility study shows many providers intended to continue using the tool, although some said they did not have sufficient time or did not need the tool.

Olalekan Ajayi, PharmD, MBA, chief operating officer of Highlands Oncology Group, PA, and 2023-2024 president-elect of the Association of Community Cancer Centers (ACCC), discusses why he is excited for this year’s meeting, including its many workshops and day 1 keynote on CRISPR.

Carolina Blood and Cancer Care Associates’ No One Left Alone initiative works to dismantle cancer health disparities and increase health care equity among its rural patient population. Sashi Naidu, MD, director of research, discusses delivering next-generation sequencing testing to patients.

The researchers used Paraphase on more than 400 samples of spinal muscular atrophy (SMA) comprising 5 ethnicities.

A diagnostic algorithm was evaluated for its ability to gauge the presence of asthma or chronic obstructive pulmonary disease (COPD), in a new analysis.

Having a diagnostic model that leverages artificial intelligence could fill a gap in the pulmonary hypertension (PH) diagnostic pathway, as there are currently just 2 validated screening algorithms for PH.

Utilizing real-world evidence that applies to the specific care needs of certain patient populations can promote timely decision-making among payers and providers on the use of effective cancer therapies available on the market, said panelists at the 2022 Patient-Centered Oncology Care® (PCOC) meeting.

Patients with heart failure and high comorbidity burdens who received postdischarge noninvasive telemonitoring and nurse telephone coaching showed better survival outcomes than those who received standard care.

This agreement enables the integration of data from Dexcom’s continuous glucose monitor (CGM) directly into DarioHealth's metabolic digital health tool, adding another layer of support.

This exploration of eczema self-management investigated the potential effectiveness of 2 online behavioral interventions, 1 each for young patients and their parents and/or caregivers.

Michael N. Cohen, MD, FAAO, retinal surgeon at Wills Eye Hospital in Philadephia and Mid Atlantic Retina, speaks about the future of gene therapy and the accessibility and availability of these therapies moving forward.

The Angiogenesis, Exudation, and Degeneration 2023 meeting will be held virtually with a program focused on understanding and treating neovascular, exudative, and degenerative diseases of the eye.

The report helps clarify the urban/rural divide in cancer outcomes and the digital divide in telehealth access.

Artificial intelligence (AI) improved detection of actionable lung nodules without leading to higher rates of false positives, the study found.

Virtual care not only means saved time and costs for employees, but improvements to employers' bottom lines, through more proactive management of health concerns, notes UCM Digital Health CEO and co-founder Keith Algozzine.

Developing a terminology strategy that reflects real-world practice and industry standards can help data scientists and other allied data professionals efficiently and accurately identify clinically relevant insights that help improve the health of populations and individual patients.

This new study examined uptake and use of a digital tool meant to aid in diabetes prevention.

First steps include assembling equity data and reaching out to veterans’ advocacy groups.

A letter from the guest editor highlights the potential for the findings in this special issue help us take steps toward realizing the promise of information technology in health care.

The report also suggests that ataxia telangiectasia and Rad3-related protein inhibition could be a valuable tool to overcome resistance.

Clinical calculators that do not include demographic variables may be biased, and their equity should be understood in the context of clinical guidelines.